JP2009523414A - 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用 - Google Patents
細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用 Download PDFInfo
- Publication number
- JP2009523414A JP2009523414A JP2008546448A JP2008546448A JP2009523414A JP 2009523414 A JP2009523414 A JP 2009523414A JP 2008546448 A JP2008546448 A JP 2008546448A JP 2008546448 A JP2008546448 A JP 2008546448A JP 2009523414 A JP2009523414 A JP 2009523414A
- Authority
- JP
- Japan
- Prior art keywords
- dha
- use according
- acid
- epa
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004792 oxidative damage Effects 0.000 title claims abstract description 51
- 230000003902 lesion Effects 0.000 title claims abstract description 24
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 634
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 332
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 306
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 72
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 51
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000002253 acid Substances 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 14
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 197
- 230000000694 effects Effects 0.000 claims description 123
- 230000003078 antioxidant effect Effects 0.000 claims description 67
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 60
- 108091035539 telomere Proteins 0.000 claims description 49
- 210000003411 telomere Anatomy 0.000 claims description 49
- 102000055501 telomere Human genes 0.000 claims description 49
- 239000003963 antioxidant agent Substances 0.000 claims description 47
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 43
- 229930195729 fatty acid Natural products 0.000 claims description 43
- 239000000194 fatty acid Substances 0.000 claims description 43
- 150000004665 fatty acids Chemical class 0.000 claims description 43
- 150000003626 triacylglycerols Chemical class 0.000 claims description 29
- 230000001413 cellular effect Effects 0.000 claims description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 23
- 239000008103 glucose Substances 0.000 claims description 23
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 108020004414 DNA Proteins 0.000 claims description 20
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- -1 diglyceride Chemical compound 0.000 claims description 20
- 238000004904 shortening Methods 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 235000011007 phosphoric acid Nutrition 0.000 claims description 12
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 7
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 7
- 206010063493 Premature ageing Diseases 0.000 claims description 6
- 208000032038 Premature aging Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 239000003223 protective agent Substances 0.000 claims description 5
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000004494 ethyl ester group Chemical group 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 230000037147 athletic performance Effects 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 230000007654 ischemic lesion Effects 0.000 claims description 3
- 230000008811 mitochondrial respiratory chain Effects 0.000 claims description 3
- 230000000626 neurodegenerative effect Effects 0.000 claims description 3
- 208000013441 ocular lesion Diseases 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 17
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 55
- 230000036542 oxidative stress Effects 0.000 description 45
- 102000019197 Superoxide Dismutase Human genes 0.000 description 44
- 108010012715 Superoxide dismutase Proteins 0.000 description 44
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 43
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 39
- 235000006708 antioxidants Nutrition 0.000 description 38
- 238000002474 experimental method Methods 0.000 description 37
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 34
- 210000003953 foreskin Anatomy 0.000 description 33
- 230000003834 intracellular effect Effects 0.000 description 29
- 239000002609 medium Substances 0.000 description 29
- 102000006587 Glutathione peroxidase Human genes 0.000 description 25
- 108700016172 Glutathione peroxidases Proteins 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 22
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 22
- 230000001590 oxidative effect Effects 0.000 description 22
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 20
- 229960003180 glutathione Drugs 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- 210000002950 fibroblast Anatomy 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 230000007423 decrease Effects 0.000 description 17
- 230000006698 induction Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 238000007254 oxidation reaction Methods 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000003647 oxidation Effects 0.000 description 13
- 108010024636 Glutathione Proteins 0.000 description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000006851 antioxidant defense Effects 0.000 description 10
- 229940012843 omega-3 fatty acid Drugs 0.000 description 10
- 229940075420 xanthine Drugs 0.000 description 10
- 102100033220 Xanthine oxidase Human genes 0.000 description 9
- 108010093894 Xanthine oxidase Proteins 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 9
- 239000006014 omega-3 oil Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 235000021588 free fatty acids Nutrition 0.000 description 8
- 125000005456 glyceride group Chemical group 0.000 description 8
- 239000007800 oxidant agent Substances 0.000 description 8
- 230000003244 pro-oxidative effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 7
- 239000013592 cell lysate Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003859 lipid peroxidation Effects 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 6
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 6
- 108010053835 Catalase Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- KJQFBVYMGADDTQ-UHFFFAOYSA-N S-butyl-DL-homocysteine (S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- AJIVVDSJIOOZOJ-UHFFFAOYSA-N 3',6'-diacetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid Chemical compound O1C(=O)C2=CC(C(O)=O)=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 AJIVVDSJIOOZOJ-UHFFFAOYSA-N 0.000 description 5
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 5
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 108091008695 photoreceptors Proteins 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010053070 Glutathione Disulfide Proteins 0.000 description 4
- 108010063907 Glutathione Reductase Proteins 0.000 description 4
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000000270 basal cell Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000007323 disproportionation reaction Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 3
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 102000003820 Lipoxygenases Human genes 0.000 description 3
- 108090000128 Lipoxygenases Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108091006300 SLC2A4 Proteins 0.000 description 3
- 108010017842 Telomerase Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000013142 basic testing Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 230000037078 sports performance Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 208000037051 Chromosomal Instability Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 2
- 241001421711 Mithras Species 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229940097156 peroxyl Drugs 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- SFWZZSXCWQTORH-UHFFFAOYSA-N 1-methyl-2-phenylindole Chemical compound C=1C2=CC=CC=C2N(C)C=1C1=CC=CC=C1 SFWZZSXCWQTORH-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 101000836247 Aquifex pyrophilus Superoxide dismutase [Fe] Proteins 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 description 1
- 102100039212 Myocyte-specific enhancer factor 2D Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001167 Poly(triaryl amine) Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MIAUJDCQDVWHEV-UHFFFAOYSA-N benzene-1,2-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1S(O)(=O)=O MIAUJDCQDVWHEV-UHFFFAOYSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000002554 cardiac rehabilitation Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ITNKVODZACVXDS-YATCGRJWSA-N ethyl (4e,7e,10e,13e,16e,19e)-docosa-4,7,10,13,16,19-hexaenoate Chemical compound CCOC(=O)CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CC ITNKVODZACVXDS-YATCGRJWSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011419 induction treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000005473 octanoic acid group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 230000007398 protein translocation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200503202A ES2277557B1 (es) | 2005-12-21 | 2005-12-21 | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| ES200602418A ES2315125B1 (es) | 2005-12-21 | 2006-09-25 | Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular". |
| ES200602417A ES2315124B1 (es) | 2005-12-21 | 2006-09-25 | Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular". |
| PCT/EP2006/070016 WO2007071733A2 (en) | 2005-12-21 | 2006-12-20 | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
| ES200603231A ES2316263B1 (es) | 2005-12-21 | 2006-12-20 | Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular". |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013192263A Division JP2014028830A (ja) | 2005-12-21 | 2013-09-17 | 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523414A true JP2009523414A (ja) | 2009-06-25 |
| JP2009523414A5 JP2009523414A5 (https=) | 2012-07-05 |
Family
ID=37728386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546448A Pending JP2009523414A (ja) | 2005-12-21 | 2006-12-20 | 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9265745B2 (https=) |
| EP (3) | EP1962825B1 (https=) |
| JP (1) | JP2009523414A (https=) |
| KR (1) | KR101256448B1 (https=) |
| CN (1) | CN101346138B (https=) |
| AU (1) | AU2006327064B2 (https=) |
| BR (1) | BRPI0621131A2 (https=) |
| CA (1) | CA2632949C (https=) |
| ES (1) | ES2384701T3 (https=) |
| IL (1) | IL192154A (https=) |
| MX (1) | MX2008008171A (https=) |
| NO (1) | NO341240B1 (https=) |
| NZ (1) | NZ569676A (https=) |
| PL (1) | PL1962825T3 (https=) |
| RU (1) | RU2437583C2 (https=) |
| WO (1) | WO2007071733A2 (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014512351A (ja) * | 2011-03-29 | 2014-05-22 | パルパ・メディカル・リミテッド | 神経障害の治療用組成物 |
| JP2016513136A (ja) * | 2013-02-28 | 2016-05-12 | アニダ ファーマ インコーポレイテッド | 聴器毒性を治療する方法 |
| WO2019106865A1 (ja) * | 2017-12-01 | 2019-06-06 | 国立大学法人九州大学 | アシルステリルグルコシド、アシルステリルグルコシドの製造方法、組成物、抗酸化剤、発毛又は育毛剤、血中脂質低下剤、抗肥満剤、抗腫瘍剤及びアテローム性動脈硬化症の予防又は治療剤 |
| JP2020023700A (ja) * | 2013-12-18 | 2020-02-13 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 長鎖多価不飽和脂肪酸を含む脂質 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| EP1962825B1 (en) | 2005-12-21 | 2014-04-02 | Brudy Technology, S.L. | Use of dha for treating a pathology associated with cellular oxidative damage |
| US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| US8207363B2 (en) | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
| CA2756528A1 (en) * | 2009-04-17 | 2010-10-21 | Celavista Pharmaceuticals Limited | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
| US9924733B2 (en) | 2010-01-19 | 2018-03-27 | Dsm Ip Assets B.V. | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof |
| US20160310456A1 (en) * | 2013-03-12 | 2016-10-27 | Physicians Recommended Nutriceuticals, Llc | Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure |
| US10709680B2 (en) * | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| AU2012285806B2 (en) | 2011-07-21 | 2017-09-14 | Dsm Ip Assets B.V. | Fatty acid compositions |
| CN103585140A (zh) * | 2013-11-22 | 2014-02-19 | 苏州麦可旺志生物技术有限公司 | Epa在制备溴酸钾诱导氧化应激性肾损伤药物中的应用 |
| US11718577B2 (en) | 2013-12-18 | 2023-08-08 | Commonwealth Scientific And Industrial Research Organisation | Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids |
| EP3906920A1 (en) | 2014-06-06 | 2021-11-10 | Marine Ingredients, LLC | Omega-3 compositions, dosage forms, and methods of use |
| KR20180051737A (ko) * | 2016-11-08 | 2018-05-17 | 차의과학대학교 산학협력단 | 대장염-관련 암 발생을 줄이는 ω-3 폴리불포화지방산 활성 성분으로 포함하는 항암 조성물 |
| US20170156280A1 (en) | 2017-02-13 | 2017-06-08 | Bayer Cropscience Lp | Cotton variety st 5517gltp |
| US20170150690A1 (en) | 2017-02-13 | 2017-06-01 | Bayer Cropscience Lp | Cotton variety fm 1888gl |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| CN110846346B (zh) | 2019-11-26 | 2021-06-22 | 瞿瀚鹏 | 富含Sn-2位DHA的微生物油脂及其制备方法和应用 |
| AU2022322112A1 (en) * | 2021-08-04 | 2024-03-07 | Leiutis Pharmaceuticals Llp | Novel omega 3 carrier preparations for inhalation drug delivery for treating lung inflammation |
| CN113749255B (zh) * | 2021-09-15 | 2022-11-29 | 江南大学 | 一种磷脂组合物在修复肌肉损伤的应用 |
| WO2023122827A1 (en) * | 2021-12-28 | 2023-07-06 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| CN116687902A (zh) * | 2023-06-14 | 2023-09-05 | 浙江大学 | Dha在制备促进心肌细胞增殖和心脏再生产品中的应用 |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2218984A (en) * | 1988-05-27 | 1989-11-29 | Renafield Limited | High-concentration mixtures of polyunsaturated fatty acids and their esters derived from animal &/or vegetable oils, & their prophylactic or therapeutic uses |
| JPH0249723A (ja) * | 1988-04-18 | 1990-02-20 | Taiyo Fishery Co Ltd | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| JPH07255417A (ja) * | 1994-03-25 | 1995-10-09 | Kanebo Ltd | 機能性健康食品 |
| JPH08511533A (ja) * | 1993-06-09 | 1996-12-03 | マーテック・バイオサイエンスィズ・コーポレーション | 神経学的障害の治療に有用な方法および医薬用組成物 |
| JPH0977782A (ja) * | 1995-09-11 | 1997-03-25 | Asahi Chem Ind Co Ltd | ドコサヘキサエン酸を構成脂肪酸とするリン脂質の製造方法 |
| JPH1072590A (ja) * | 1995-09-14 | 1998-03-17 | Agency Of Ind Science & Technol | （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途 |
| WO1998028978A1 (en) * | 1996-05-08 | 1998-07-09 | Weider Nutrition Group, Inc. | Structured glycerols and structured phosphatides |
| JPH11239464A (ja) * | 1997-06-16 | 1999-09-07 | Nippon Suisan Kaisha Ltd | 運動時の危険因子除去能を有する組成物 |
| JPH11239465A (ja) * | 1997-06-16 | 1999-09-07 | Nippon Suisan Kaisha Ltd | 健常人が運動能力を高める食品 |
| JP2002040014A (ja) * | 2000-07-19 | 2002-02-06 | Nippon Steel Corp | 炭素含有耐火物の耐摩耗性、耐食性及び耐酸化性の評価方法 |
| JP2002537252A (ja) * | 1999-02-17 | 2002-11-05 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | 心血管事象を予防するための必須脂肪酸 |
| WO2003068216A1 (en) * | 2002-02-12 | 2003-08-21 | Victorix Assets Ltd. | The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure |
| WO2004112776A2 (en) * | 2003-06-23 | 2004-12-29 | Advanced Bionutrition (Europe) Limited | Inflammatory disease treatment |
| JP2005000033A (ja) * | 2003-06-10 | 2005-01-06 | Shinbijuumu:Kk | 食品 |
| WO2005013908A2 (en) * | 2003-08-05 | 2005-02-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration |
| JP2005068060A (ja) * | 2003-08-22 | 2005-03-17 | Nrl Pharma Inc | ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法 |
| JP2008540484A (ja) * | 2005-05-12 | 2008-11-20 | プロイェクト、エンプレサリアル、ブルーディ、ソシエダッド、リミターダ | 腫瘍性疾患の治療のためのドコサヘキサエン酸グリセリドの使用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
| SE9101642D0 (sv) * | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
| CA2119000A1 (en) * | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
| US20050027004A1 (en) * | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| FR2731015B1 (fr) * | 1995-02-24 | 1997-05-30 | Sci Sartone | Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus |
| US6582941B1 (en) * | 1995-04-17 | 2003-06-24 | Japan As Represented By Director-General Of Agency Of Industrial Science And Technology | Microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fatty acids by using the microorganisms |
| MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| US6509178B1 (en) * | 1996-07-23 | 2003-01-21 | Suntory Ltd. | Process for preparing docosahexaenoic acid and docosapentaenoic acid with ulkenia |
| US6313167B1 (en) | 1997-06-16 | 2001-11-06 | Nippon Suisan Kaisha Ltd. | Composition having capability of removing risk factor during exercise |
| GB9715444D0 (en) * | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| EP1249523A1 (fr) * | 2001-04-12 | 2002-10-16 | Michel Beckers | Cylindre brouilleur et son utilisation |
| AR039170A1 (es) | 2002-03-28 | 2005-02-09 | Bio Dar Ltd | Co-granulos de dha y romero y metodos de uso |
| US20040209953A1 (en) * | 2002-12-06 | 2004-10-21 | Wai Lee Theresa Siu-Ling | Glyceride compositions and methods of making and using same |
| US7041840B2 (en) * | 2002-12-18 | 2006-05-09 | Alberta Research Council Inc. | Antioxidant triacylglycerols and lipid compositions |
| US20050130937A1 (en) * | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
| WO2005065669A1 (en) * | 2003-12-19 | 2005-07-21 | Alcon, Inc. | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
| US20050163873A1 (en) | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| ITMI20040069A1 (it) | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
| WO2006077495A1 (en) | 2005-01-24 | 2006-07-27 | Pronova Biocare As | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases |
| FR2882894B1 (fr) | 2005-03-11 | 2009-04-03 | Larena Sa | Composition alimentaire suppletive |
| EP1962825B1 (en) | 2005-12-21 | 2014-04-02 | Brudy Technology, S.L. | Use of dha for treating a pathology associated with cellular oxidative damage |
-
2006
- 2006-12-20 EP EP06841516.5A patent/EP1962825B1/en active Active
- 2006-12-20 NZ NZ569676A patent/NZ569676A/en not_active IP Right Cessation
- 2006-12-20 KR KR1020087017876A patent/KR101256448B1/ko not_active Expired - Fee Related
- 2006-12-20 US US12/158,205 patent/US9265745B2/en active Active
- 2006-12-20 WO PCT/EP2006/070016 patent/WO2007071733A2/en not_active Ceased
- 2006-12-20 EP EP11189179.2A patent/EP2510927A3/en not_active Withdrawn
- 2006-12-20 JP JP2008546448A patent/JP2009523414A/ja active Pending
- 2006-12-20 MX MX2008008171A patent/MX2008008171A/es active IP Right Grant
- 2006-12-20 CN CN2006800488216A patent/CN101346138B/zh not_active Expired - Fee Related
- 2006-12-20 RU RU2008126805/13A patent/RU2437583C2/ru active
- 2006-12-20 CA CA2632949A patent/CA2632949C/en active Active
- 2006-12-20 ES ES06841516.5T patent/ES2384701T3/es active Active
- 2006-12-20 AU AU2006327064A patent/AU2006327064B2/en not_active Ceased
- 2006-12-20 BR BRPI0621131-3A patent/BRPI0621131A2/pt not_active Application Discontinuation
- 2006-12-20 PL PL06841516T patent/PL1962825T3/pl unknown
- 2006-12-20 EP EP17180553.4A patent/EP3263101A1/en not_active Withdrawn
-
2008
- 2008-06-12 IL IL192154A patent/IL192154A/en not_active IP Right Cessation
- 2008-07-17 NO NO20083187A patent/NO341240B1/no not_active IP Right Cessation
-
2013
- 2013-03-14 US US13/803,038 patent/US9259408B2/en active Active
-
2016
- 2016-02-08 US US15/017,877 patent/US20160151258A1/en not_active Abandoned
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0249723A (ja) * | 1988-04-18 | 1990-02-20 | Taiyo Fishery Co Ltd | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| GB2218984A (en) * | 1988-05-27 | 1989-11-29 | Renafield Limited | High-concentration mixtures of polyunsaturated fatty acids and their esters derived from animal &/or vegetable oils, & their prophylactic or therapeutic uses |
| JPH08511533A (ja) * | 1993-06-09 | 1996-12-03 | マーテック・バイオサイエンスィズ・コーポレーション | 神経学的障害の治療に有用な方法および医薬用組成物 |
| JPH07255417A (ja) * | 1994-03-25 | 1995-10-09 | Kanebo Ltd | 機能性健康食品 |
| JPH0977782A (ja) * | 1995-09-11 | 1997-03-25 | Asahi Chem Ind Co Ltd | ドコサヘキサエン酸を構成脂肪酸とするリン脂質の製造方法 |
| JPH1072590A (ja) * | 1995-09-14 | 1998-03-17 | Agency Of Ind Science & Technol | （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途 |
| WO1998028978A1 (en) * | 1996-05-08 | 1998-07-09 | Weider Nutrition Group, Inc. | Structured glycerols and structured phosphatides |
| JPH11239465A (ja) * | 1997-06-16 | 1999-09-07 | Nippon Suisan Kaisha Ltd | 健常人が運動能力を高める食品 |
| JPH11239464A (ja) * | 1997-06-16 | 1999-09-07 | Nippon Suisan Kaisha Ltd | 運動時の危険因子除去能を有する組成物 |
| JP2002537252A (ja) * | 1999-02-17 | 2002-11-05 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | 心血管事象を予防するための必須脂肪酸 |
| JP2002040014A (ja) * | 2000-07-19 | 2002-02-06 | Nippon Steel Corp | 炭素含有耐火物の耐摩耗性、耐食性及び耐酸化性の評価方法 |
| WO2003068216A1 (en) * | 2002-02-12 | 2003-08-21 | Victorix Assets Ltd. | The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure |
| JP2005000033A (ja) * | 2003-06-10 | 2005-01-06 | Shinbijuumu:Kk | 食品 |
| WO2004112776A2 (en) * | 2003-06-23 | 2004-12-29 | Advanced Bionutrition (Europe) Limited | Inflammatory disease treatment |
| WO2005013908A2 (en) * | 2003-08-05 | 2005-02-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration |
| JP2005068060A (ja) * | 2003-08-22 | 2005-03-17 | Nrl Pharma Inc | ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法 |
| JP2008540484A (ja) * | 2005-05-12 | 2008-11-20 | プロイェクト、エンプレサリアル、ブルーディ、ソシエダッド、リミターダ | 腫瘍性疾患の治療のためのドコサヘキサエン酸グリセリドの使用 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014512351A (ja) * | 2011-03-29 | 2014-05-22 | パルパ・メディカル・リミテッド | 神経障害の治療用組成物 |
| JP2016513136A (ja) * | 2013-02-28 | 2016-05-12 | アニダ ファーマ インコーポレイテッド | 聴器毒性を治療する方法 |
| US9987244B2 (en) | 2013-02-28 | 2018-06-05 | Anida Pharma, Inc. | Methods of treating ototoxicity |
| JP2020023700A (ja) * | 2013-12-18 | 2020-02-13 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 長鎖多価不飽和脂肪酸を含む脂質 |
| WO2019106865A1 (ja) * | 2017-12-01 | 2019-06-06 | 国立大学法人九州大学 | アシルステリルグルコシド、アシルステリルグルコシドの製造方法、組成物、抗酸化剤、発毛又は育毛剤、血中脂質低下剤、抗肥満剤、抗腫瘍剤及びアテローム性動脈硬化症の予防又は治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| NO341240B1 (no) | 2017-09-25 |
| EP3263101A1 (en) | 2018-01-03 |
| EP1962825B1 (en) | 2014-04-02 |
| CA2632949C (en) | 2012-05-22 |
| CA2632949A1 (en) | 2007-06-28 |
| ES2384701T3 (es) | 2014-07-02 |
| ES2384701T1 (es) | 2012-07-11 |
| RU2008126805A (ru) | 2010-01-27 |
| KR101256448B1 (ko) | 2013-04-19 |
| NZ569676A (en) | 2012-03-30 |
| AU2006327064A1 (en) | 2007-06-28 |
| PL1962825T3 (pl) | 2014-09-30 |
| WO2007071733A3 (en) | 2007-09-07 |
| AU2006327064B2 (en) | 2012-04-26 |
| EP1962825A2 (en) | 2008-09-03 |
| EP2510927A2 (en) | 2012-10-17 |
| EP2510927A3 (en) | 2013-05-01 |
| RU2437583C2 (ru) | 2011-12-27 |
| KR20080081334A (ko) | 2008-09-09 |
| MX2008008171A (es) | 2008-11-12 |
| BRPI0621131A2 (pt) | 2011-11-29 |
| CN101346138A (zh) | 2009-01-14 |
| NO20083187L (no) | 2008-09-19 |
| IL192154A (en) | 2015-04-30 |
| CN101346138B (zh) | 2013-03-13 |
| US9259408B2 (en) | 2016-02-16 |
| US9265745B2 (en) | 2016-02-23 |
| WO2007071733A2 (en) | 2007-06-28 |
| US20160151258A1 (en) | 2016-06-02 |
| US20080292681A1 (en) | 2008-11-27 |
| US20130274337A1 (en) | 2013-10-17 |
| IL192154A0 (en) | 2008-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6556640B2 (ja) | 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用 | |
| US9259408B2 (en) | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage | |
| Ďuračková | Some current insights into oxidative stress. | |
| Hariri et al. | Sub-acute effects of diazinon on biochemical indices and specific biomarkers in rats: protective effects of crocin and safranal | |
| Chen et al. | Phosphatidylserine: An overview on functionality, processing techniques, patents, and prospects | |
| WO2013054267A1 (en) | Synergistic composition for preventing and treating disorders connected with ageing | |
| Martínez et al. | Novel molecular targets for the prevention of fetal alcohol syndrome | |
| KR102569055B1 (ko) | 아세트알데하이드 독성을 감소시키기 위한 베타-에스신을 포함하는 경구 조성물 | |
| WO2013086327A1 (en) | Nutritional compositions comprising curcumin and phosphatidylserine-docosahexaenoic acid for improving cognition | |
| EP3681488A1 (en) | Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder | |
| Dalimova et al. | Influence of the supramolecular complex of glycyrrhizic acid with quercetin on age-related functional changes in rat brain mitochondria | |
| Miller Jr | Ethanol-induced lipid peroxidation and apoptosis in embryopathy | |
| Gliwa | The antioxidant and anti-inflammatory activities of alkylresorcinols from rye bran | |
| Johnsen | Presented for the Master of Science Degree |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120215 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120315 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120323 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120416 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120515 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120515 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120914 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121214 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130107 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130115 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130917 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131114 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140207 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140619 |